ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced the appointment of Jeff Fried to its Advisory Board.
A recognized leader in healthcare data infrastructure and AI innovation, Jeff Fried brings more than 25 years of experience designing and delivering high-performance data for complex life sciences and clinical environments. He currently serves as Director of Platform Strategy and Innovations for InterSystems, where he helps shape high-performance data solutions for some of the world’s most demanding healthcare and life sciences environments. He has served on advisory boards for industry, government, and academia, and served as CTO for Teloquent (acquired by Syntellect), Empirix (acquired by InfoVista), and BA Insight (acquired by Upland Software), as well as product leadership roles at FAST Search and Microsoft.
Mr. Fried has been an enthusiastic advocate for IPA’s LENSai™ platform, praising its ability to unify biological sequence, structure, function, and scientific literature into a searchable, AI-ready framework. He has played a pivotal role in supporting BioStrand’s partnership with InterSystems to integrate advanced vector search capabilities into LENSai—helping unlock powerful new possibilities for AI-driven research, diagnostics, and therapeutic development.
“We are excited to welcome Jeff to our Advisory Board at a time when our vision for a scalable, bio-native AI infrastructure is rapidly becoming a reality,” said Dr. Jennifer Bath, CEO of IPA. “Jeff’s insights at the intersection of healthcare data architecture and AI-enabled discovery are invaluable as we continue to expand LENSai’s capabilities and reach across life sciences.”
“LENSai is one of the most exciting AI platforms I’ve encountered in the life sciences space,” said Fried. “It solves a foundational problem—making biological data interoperable and computationally accessible at scale. I’m thrilled to contribute to IPA’s vision and help shape the future of bio-native AI drug discovery.”
Fried’s appointment underscores IPA’s commitment to enabling discovery work at the speed of computation, not convention, by providing the bio-native AI infrastructure the life sciences industry truly needs—fast, scalable, and grounded in real biological data.